Population pharmacokinetics and exposure-response analysis of levofloxacin in Chinese pediatric patients with severe refractory Mycoplasma pneumoniae pneumonia
Abstract
ABSTRACT Levofloxacin is recommended as an optional treatment for pediatric patients with severe refractory Mycoplasma pneumoniae pneumonia (SRMPP), but its use remains off-label due to limited pharmacokinetic/pharmacodynamic (PK/PD) data in this population. This study aimed to characterize the PK/PD properties of levofloxacin in pediatric SRMPP patients and define optimal dosing regimens. Scavenged blood samples from patients aged ≤18 years were collected using opportunistic sampling strategy to develop a population pharmacokinetic (PopPK) model of levofloxacin. The Cox proportional hazards model was applied to identify the optimal AUC ss,0–24h cutoff associated with improved efficacy (shorter levofloxacin treatment duration and shorter cough resolution). Monte Carlo simulations were then performed to evaluate target attainment for this efficacy cutoff under guideline regimens (8–10 mg/kg q12 h for ages 1–5 years; 8–10 mg/kg q24 h for ages 5–16 years). A total of 191 pediatric patients (0.16–16 years) with SRMPP receiving intravenous levofloxacin were included in the PK analysis, and 161 patients were included in the exposure-response analysis. A two-compartment PopPK model was developed, identifying body weight as a significant covariate on clearance and central volume of distribution, and serum creatinine as an additional covariate on clearance. Patients with AUC ss,0–24h ≥ 30.74 mg·h/L achieved shorter levofloxacin treatment duration ( P = 0.019). Guideline-recommended…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.